microRNAs (miRNAs) have key roles in human tumorigenesis, tumor progression and metastasis. miRNAs are aberrantly expressed in many human cancers and can function as tumor suppressors or oncogenes that target many cancer-related genes. This study seeks to identify novel miRNA-regulated molecular pathways in prostate cancer (PCa). The miRNA expression signature in clinical specimens of PCa showed that 56 miRNAs were significantly downregulated in PCa compared with nonPCa tissues. We focused on the top four downregulated miRNAs (miR-187, miR-205, miR-222 and miR-31) to investigate their functional significance in PCa cells. Expression levels of these four miRNAs were validated in PCa specimens (15 PCa tissues and 17 non-PCa tissues) to confirm that they were significantly reduced in these PCa tissues. Gain-of-function analysis demonstrated that miR-222 and miR-31 inhibited cell proliferation, invasion and migration in PCa cell lines (PC3 and DU145), suggesting that miR-222 and miR-31 may act as tumor suppressors in PCa. Genome-wide gene expression analysis using miR-222 or miR-31 transfectants to identify the pathways they affect showed that many cancer-related genes are regulated by these miRNAs in PC3 cells. Identification and categorization of the molecular pathways regulated by tumor suppressive miRNAs could provide new information about the molecular mechanisms of PCa tumorigenesis.
INTRODUCTION
Prostate cancer (PCa) is the most frequently diagnosed cancer and second leading cause of cancer death among men in developed countries. 1 In early-stage PCa, more than 90% of patients initially respond to the therapeutic use of androgen deprivation; however, many cases become refractory and progress to androgen-independent PCa. 2 Hormone-refractory PCa often involves disease progression and metastasis to the bones or other sites and is currently difficult to treat. As most clinical trials for advanced PCa have shown limited benefits, 3,4 new prognostic markers and effective treatment strategies are urgently needed. Understanding the molecular pathways underlying PCa could significantly improve diagnosis, therapy and disease prevention.
miRNAs are a class of small non-coding RNA molecules consisting of [19] [20] [21] [22] nucleotides that are involved in a variety of biological processes, including development, differentiation, apoptosis and cell proliferation. miRNAs regulate gene expression through translational repression and mRNA cleavage 5 with bioinformatic predictions indicating that miRNAs regulate more than 60% of protein coding genes. 6 To date, 1527 human miRNAs have been registered in the miRBase release 18.0 (http:// microrna.sanger.ac.uk/). miRNAs also contribute to the initiation and development of various types of cancers. Many human cancers have aberrant expression of miRNAs, which can function either as tumor suppressors or oncogenes. 7, 8 In cancer pathways, normal regulatory mechanisms are disrupted by altered expression of tumor suppressive or oncogenic miRNAs.
Recently, we sequentially identified tumor suppressive miRNAs in several types of cancers, such as head and neck squamous cell carcinoma, 9 ,10 esophageal squamous cell carcinoma, 11 bladder cancer, 12, 13 renal cell carcinoma 14 and PCa 15 and described the molecular pathways they regulate. Our analysis of miRNA-regulated cancer pathways provided novel insights for diagnostic and therapeutic strategies for these cancers.
In this study we identified tumor suppressive miRNAs in PCa based on the miRNA expression signature in clinical PCa specimens. The evaluation of 778 mature miRNAs from PCa specimens revealed that 57 miRNAs had significantly reduced expression. Gain-offunction analysis demonstrated that miR-222 and miR-31 inhibited cell proliferation, invasion and migration in PCa cell lines (PC3 and DU145). Furthermore, we used genome-wide gene expression analysis to identify target genes of tumor suppressive miR-222 or miR-31 and determine whether these miRNAs regulate cancer pathways. The identification of tumor suppressive miRNAs and their corresponding molecular pathways could provide new insights into PCa tumorigenesis.
MATERIALS AND METHODS

Clinical prostate specimens
Clinical specimens were obtained from patients at Teikyo University Chiba Medical Center Hospital from 2008 to 2010. All patients had elevated serum levels of prostate-specific antigen and had undergone transrectal prostate needle biopsy. Prostatic cancerous tissues (PCa, n ¼ 20) and non-cancerous tissues (non-PCa, n ¼ 22) were used in this study. Among these, five PCa (no. 1-5) and five non-PCa (no. 21-25) samples were used for miRNA expression analysis and the remainder was used to validate selected miRNA expression levels. Patient characteristics and representative pathological features are shown in Table 1 and Figure 1 , respectively. Written consent for tissue donation for research purposes was obtained from patients before tissue collection. The protocol was approved by the Institutional Review Board of Teikyo University. To confirm tissue composition, a pair of needle biopsy specimens was collected from the same region in the patients, and one sample was subjected to pathological validation. No cancerous tissue was found in non-PCa specimens.
miRNA expression signatures and data normalization miRNA expression patterns were evaluated using the TaqMan LDA Human microRNA Panel v2.0 with a total of 778 miRNAs investigated in the screen (Applied Biosystems, Foster City, CA, USA). The assay consisted of two steps: cDNA generation by reverse transcription and a TaqMan real-time PCR assay. The description of real-time PCR and the list of human miRNAs can be found on the company's website (http://www.appliedbiosystems.com). An analysis of relative miRNA expression data was performed using GeneSpring GX software version 7.3.1 (Agilent Technologies, Santa Clara, CA, USA), according to the manufacturer's instructions. A cutoff P value o0.05 was used to narrow the candidates after normalization of the raw data. Normalization was done with respect to RNU6B.
Cell culture
We used human PCa cell lines (PC3 and DU145), which were obtained from the American Type Culture Collection (Manassas, VA, USA) and maintained in RPMI-1640 medium supplemented with 10% fetal bovine serum in a humidified atmosphere of 5% CO 2 and 95% air at 37 1C.
RNA extraction
Total RNA including miRNA was extracted using the mirVana miRNA isolation kit (Ambion, Austin, TX, USA) according to the manufacturer's protocol. RNA integrity was checked with the RNA 6000 Nano Assay Kit and a 2100 Bioanalyzer (Agilent Technologies).
Quantitative real-time RT-PCR
For miRNA quantitation we used TaqMan quantitative real-time PCR (TaqMan MicroRNA Assay; Applied Biosystems). The cDNA strand was synthesized from total RNA (10 ng). Thermal cycling conditions were as follows: 95 1C for 15 s and 63 1C for 1 min. The expression levels of miR-187 (assay ID: 001193), miR-205 (assay ID: 000509), miR-222 (assay ID: 002276) and miR-31 (assay ID: 002279) were normalized with respect to RNU6B (assay ID: 001973). All reactions were performed in triplicate and negative controls lacking cDNA were included. The data were analyzed with the delta-delta Ct method to calculate the fold-change. For the internal controls, we examined the unevenness between the clinical samples and adapted them for use with RNU6B in this study.
Mature miRNA transfection
Pre-miR and negative-control miRNA (Applied Biosystems) were used for gain-of-function experiments. As previously described, 13 PC3 and DU145 cells were transiently transfected with precursors of miRNA-187, miR-205, miR-222, miR-31 or negative control using Lipofectamine RNAiMAX transfection reagent (Invitrogen, Carlsbad, CA, USA) according to the manufacturer's recommendations. Mock transfections, which had only the transfection Tumor suppressive microRNAs in prostate cancer M Fuse et al reagent, were also used as controls. The transfection efficiency of miRNA into cancer cells was evaluated by downregulation of PTK9 mRNA by miR-1 transfection level as described previously. 13 Cells were seeded in six-well plates for mRNA and wound healing assays (25 Â 10 4 cells per well) and in 96-well plates for XTT assays (3000 cells per well).
Cell proliferation, migration and invasion assays
Cell proliferation was determined using an XTT assay (Roche Applied Sciences, Tokyo, Japan) performed according to the manufacturer's instructions. Cell migration activity was evaluated with a wound-healing assay. Cells were plated in six-well dishes, and the cell monolayers were scraped using a P-20 micropipette tip. The initial gap length (0 h) and residual gap length 24 h after wounding were calculated from photomicrographs as described previously. 15, 16 A cell invasion assay was carried out using modified Boyden Chambers consisting of transwell-precoated Matrigel membrane filter inserts with 8 mm pores in 24-well tissue culture plates (BD Biosciences, Bedford, MA, USA). Minimum essential medium containing 10% fetal bovine serum in the lower chamber served as the chemoattractant, as described previously. 15, 16 All experiments were performed in triplicate.
Statistical analysis
The relationship between two variables and the numerical values obtained by real-time RT-PCR were analyzed using the Mann-Whitney U-test. The relationship among three variables and the numerical values were analyzed using the Bonferroni-adjusted Mann-Whitney U-test. Expert StatView analysis software (version 4; SAS Institute Inc., Cary, NC, USA) was used in both cases. For comparisons among three variables, a nonadjusted statistical level of significance of Po0.05 corresponds to a Bonferroni-adjusted level of Po0.0167.
Identification of miR-222 or miR-31 regulated target genes and bioinformatic analysis
To gain further insight into which genes were affected by miR-222 or miR-31, we performed genome-wide gene expression analysis using miR-222 or miR-31 transfectants in PC cells. Oligo-microarray human 44 K (Agilent) was used for gene expression analysis, and procedure of the experiment as described previously. 15, 16 To identify the biological processes or pathways potentially regulated by selected miRNAs, we performed GeneCodis analysis (http://genecodis. dacya.ucm.es/) with our predicted target list. Then, to develop the networks among the miRNAs and their target genes, we analyzed and characterized those genes in KEGG (Kyoto Encyclopedia of Genes and Genomes) pathway categories.
RESULTS
Identification of downregulated miRNAs in PCa in miRNA signatures
We evaluated mature miRNA expression levels of prostate clinical specimens (five PCa tissues, no. 1-5, and five non-PCa tissues, no. 21-25) by miRNA signatures (Table 1 ). Figure 1 shows the typical needle biopsies that used for expression analysis in this study. Expression signatures revealed that 56 miRNAs were downregulated in PCa samples (Table 2) . Of those, the top four miRNAs (miR-187, miR-205, miR-222 and miR-31) were subjected to further study. The fifth most downregulated miRNA, miR-133a, was excluded as it was detected as a tumor suppressive miRNA in PCa in our previous study. 15 Validation of miR-187, miR-205, miR-222 and miR-31 expression levels by quantitative stem-loop RT-PCR Relative expression levels of the top four downregulated miRNAs (miR-187, miR-205, miR-222 and miR-31) were analyzed in 15 PCa clinical samples compared with 17 non-PCa clinical samples ( Table 1 ). All of these miRNAs were significantly downregulated in the PCa specimens (Figure 2 ). In the PCa cell line PC3, the expression levels of these four miRNAs were low and nearly equivalent to those of the PCa clinical samples (data not shown).
Effects of miR-187, miR-205, miR-222 and miR-31 restoration on cell proliferation, migration and invasion in PCa cell lines To investigate the functional role of the four downregulated miRNAs in PCa, we performed gain-of-function studies using mature miRNA (Figures 3a and d) .
A wound healing assay showed significant suppression of PC3 cell migration in miR-222-or miR-31-transfected PC3 cells compared with that of mock transfectants (the percentage of wound closure relative to mock was 47.6±6.4% for miR-222 transfectants, and 53.6 ± 16.6% for miR-31 transfectants, Po0.0001), but no significant inhibition of wound closure was found in miR-187-or miR-205-transfectants in PC3 cells (Figure 3b (Figure 3e ). No significant inhibition of wound closure was found in miR-187-transfectants in DU145 cells.
A Matrigel invasion assay showed significant inhibition of PC3 cell invasion activity in miR-222-or miR-31-transfected PC3 cells compared with that of mock transfectants (the percentage of invasion cell number relative to mock was 4.4 ± 1.9% for miR-222 transfectants and 8.4 ± 3.6% for miR-31 transfectants, Po0.0001), but miR-187 or miR-205 transfectants showed no significant inhibition of cell invasion (Figure 3c) . In DU145 cells, this assay showed that significant inhibition the cell invasion activity in miR-205, miR-222 or miR-31-transfectants compared with that of mock transfectants (the percentage of invasion cell number relative to mock was 27.7 ± 3.7% for miR-205 transfectants, 26.3 ± 9.4% for miR-31 transfectants and 32.2±6.7%, Po0.0001), but miR-187 transfectant showed no significant inhibition of cell invasion (Figure 3f ).
Search for candidate pathways of miR-222 or miR-31 by genomewide gene expression and in silico analysis We performed a genome-wide gene expression analysis of miR-222 or miR-31 transfected PC3 cells. In miR-222 transfectants, 242 genes were downregulated (fold changes o À1.0) while miR-31 transfectants had 694 genes downregulated compared with negative control miRNA transfectants. The current microarray data were approved by the GEO (Gene Expression Omnibus) and were assigned GEO accession number GSE37119. In this study, we have applied in silico analysis to identify the biological processes or pathways potentially regulated by miR-222 or miR-31. These candidate target genes were assigned to pathways using GENECODIS software analysis (http://genecodis.cnb. csic.es), and statistically enriched pathways were identified. The GENECODIS software assigned a great many of the putative miR-222 or miR-31 targets to known pathways in KEGG, and these data facilitate the understanding of miRNA-regulated molecular pathways in human PCa cells. According to the GENECODIS software analysis, several pathways were identified, such as 'pathways in cancer' , 'focal adhesion' , and 'regulation of the actin cytoskeleton' (Table 3) . We focused on the 'focal adhesion' , and 'regulation of the actin cytoskeleton' , as these were identified as enriched pathway both miR-222 and miR-31 target genes (Figures 4 and 5) . 
DISCUSSION
In this study we constructed miRNA expression signatures of clinical PCa specimens using 778 miRNAs by PCR-based analysis. Among these, 56 miRNAs were downregulated compared with non-PCa specimens (log2 ratio o À1.0 and Po0.05) and several miRNAs that we previously reported to be tumor suppressive in PCa, such as miR133a, miR-1 and miR-145 were included in this signature. 15, 17, 18 Interestingly, miR-1 and miR-133a have the same chromosomal locus in the human genome and miR-1 and miR-133a downregulation is a frequent event in several cancers. 19 Our previous studies indicated that both miRNAs function as tumor suppressors that target multiple oncogenes. 12, 20, 21 Recent reports also indicated that miR-1 acts as a tumor suppressor in PCa by influencing multiple cancer-related processes and inhibiting cell proliferation and motility. 22 We also reported miR-145 downregulation in many types of human cancers, including PCa, suggesting that miR-145 functions as a tumor suppressor. Indeed, miR-145 is a widely accepted tumor suppressor in human cancers and targets various oncogenes in cancer cells. 17, 18, 23, 24 The miRNA signature described here includes approved miRNAs that are downregulated in human cancers, including PCa, and indicates the effectiveness of this signature for cancer research.
Among the downregulated miRNAs present in this signature, the top four downregulated miRNAs (miR-187, miR-205, miR-222 and miR-31) were evaluated to determine whether they had potential tumor suppressor functions (the fifth most downregulated miRNA, miR-133a, we previously reported to be a tumor suppressive miRNA in PCa). Our functional screening revealed that two miRNAs (miR-31 and miR-222) significantly inhibited cell proliferation, migration and Tumor suppressive microRNAs in prostate cancer M Fuse et al invasion in PCa cell lines (PC3 and DU145) commonly, suggesting that these two miRNAs could be tumor suppressive miRNAs in PCa. miR-222 is located close to miR-221 and together they form a cluster on human chromosome X. miR-222 has been reported to be upregulated in several types of human tumors, such as glioblastoma, non-small lung cancer and hepatocellular cancer. Regarding PCa, miR-222 has been demonstrated to be highly expressed in androgenindependent PCa cells, compared with androgen-dependent PCa cells. 25, 26 miR-222 was also reported to reduce dihydrotestosteroneindependent cell growth by directly targeting the cell cycle inhibitor p27/kip1, suggesting that miR-222 might contribute to the development of castration-resistant PCa. 25 However, several articles also showed downregulation of miR-222 in androgen-dependent PCa cells. 27, 28 In the present study, miR-222 was significantly downregulated in PCa specimens compared with non-PCa specimens and restoration of miR-222 produced significant inhibition of proliferation, migration and invasion in PC3 and DU145 cells.
Downregulation of miR-31 has been reported in various types of cancers, such as breast, 29 ovary, 30 stomach 31 and prostate. 32 Furthermore, homozygous loss of the miR-31-encoding genomic locus has been described in human urothelial carcinoma 33 and acute lymphoblastic lymphoma. 34 On the other hand, several studies showed that miR-31 is upregulated in colorectal cancer, hepatocellular cancer and most squamous cell carcinomas. To date, considerable evidence has revealed the important roles of miR-31 in cancer, but whether this miRNA functions as a tumor suppressor or an oncogene differs according to cancer type. miR-31 reportedly contributes to apoptosis resistance in PCa cells by targeting the antiapoptotic protein E2F6 29, 35 and can antagonize metastasis by suppressing expression levels of ITGA5, RDX and RhoA in breast cancer. 36 Interestingly, our functional analyses showed that restoration of miR-31 in PCa cell lines inhibited cell migration and invasion more significantly than cell proliferation, suggesting that miR-31 may also contribute to cancer invasion and metastasis in PCa.
At present, several studies have investigated aberrant expression of miRNAs based on expression signatures in PCa samples. 27, [37] [38] [39] Interestingly, our miRNA expression data were highly consistent with those of a previous study, 32 which found that miR-205, miR-222 and miR-31 were underexpressed in PCa. Genome-wide miRNA expression signatures can rapidly and precisely reveal aberrant expression of miRNA in cancers. The presence of common downregulated miRNAs on plural platforms provides important information for future analyses of PCa.
miRNAs are unique in their ability to regulate many protein coding genes with bioinformatic predictions indicating that miRNAs regulate more than 60% of protein coding genes. 6 The elucidation of new molecular pathways regulated by tumor suppressive miR-222 or miR-31 will be important for our understanding of PCa tumorigenesis. As such, we performed genome-wide gene expression and in silico analyses to search for molecular pathways regulated by miR-222 or miR-31. However, as gene expression analysis can identify very large numbers of genes, to identify the biological processes or pathways potentially regulated by miR-222 or miR-31 in Figure 5 Putative miR-222 and miR-31 target genes in 'Focal adhesion' from KEGG. The genes, putative miR-222 target genes (yellow), miR-31 (orange) and both miR-222 and miR-31 (red) as defined by the KEGG pathway and determined through GENECODIS analysis.
Tumor suppressive microRNAs in prostate cancer M Fuse et al PCa cells, we conducted a GeneCodis analysis 40 of our miR-222 or miR-31 transfectant expression profiles. The GeneCodis analysis applies many genes to known pathways in KEGG, 41 and these data facilitate understanding of tumor suppressive, miRNA-regulated molecular networks in cancer. According to the GeneCodis analysis, 'focal adhesion' and 'regulation of actin-cytoskeleton' categories were affected by both miRNA-regulated pathways. It is not easy to understand the functional significance of enormous genes which miRNA regulated in cancer cells. Like our current study, several groups reported that numerical target genes regulated by tumor suppressive miRNAs (miR-222 or miR-31) were applied on the commonly accepted molecular pathways. [42] [43] [44] [45] This approach provides new information and contributes to understand of the relation of human tumorigenesis and tumor suppressive miRNAs. In this study, both tumor suppressive miR-222 and miR-31 contributed to cancer cell migration and invasion and these pathways may participate in this phenomenon. Functional analysis of these pathways will be important for further understanding of PCa tumorigenesis, invasion and metastasis.
In conclusion, miR-187, miR-205, miR-222 and miR-31 were significantly downregulated in the PCa miRNA expression signature, with miR-222 and miR-31 functioning as tumor suppressors in PCa. The tumor suppressive, miRNA-regulated novel pathways in human PCa could provide new information concerning the molecular mechanisms of PCa tumorigenesis as well as tumor progression and metastasis.
